Pyxis Oncology (PYXS) Capital Leases (2024 - 2025)
Pyxis Oncology (PYXS) posted quarterly Capital Leases of $23000.0 for Q4 2025, down 77.0% year-over-year from $100000.0 in Q4 2024, and down 46.51% quarter-over-quarter from $43000.0 in Q3 2025.
Pyxis Oncology (PYXS) Capital Leases (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Capital Leases for 2 consecutive years, with $23000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Capital Leases fell 77.0% year-over-year to $23000.0; the TTM figure through Dec 2025 stood at $23000.0 (down 77.0% YoY), while the FY2025 annual figure was $23000.0, down 77.0% from the prior year.
- Capital Leases eased to $23000.0 in Q4 2025 per PYXS's latest filing, from $43000.0 in the prior quarter.
- Across five years, Capital Leases topped out at $135000.0 in Q2 2024 and bottomed at $23000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 135,000.00 |